Blood biomarkers for Alzheimer's disease in clinical practice and trials
Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
Blood‐based markers (BBMs) have recently shown promise to revolutionize the diagnostic
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …
Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central
nervous system of unknown etiology. We tested the hypothesis that MS is caused by Epstein …
nervous system of unknown etiology. We tested the hypothesis that MS is caused by Epstein …
Blood‐based biomarkers for Alzheimer's disease
Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Executive summary The number of older people, including those living with dementia, is
rising, as younger age mortality declines. However, the age-specific incidence of dementia …
rising, as younger age mortality declines. However, the age-specific incidence of dementia …
[HTML][HTML] Ofatumumab versus teriflunomide in multiple sclerosis
Background Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …
Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19
Objective To test the hypothesis that coronavirus disease 2019 (COVID-19) has an impact
on the CNS by measuring plasma biomarkers of CNS injury. Methods We recruited 47 …
on the CNS by measuring plasma biomarkers of CNS injury. Methods We recruited 47 …
Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies
Biomarkers of neurodegeneration and neuronal injury have the potential to improve
diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy …
diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy …
Serum neurofilament light levels in normal aging and their association with morphologic brain changes
M Khalil, L Pirpamer, E Hofer, MM Voortman… - Nature …, 2020 - nature.com
Neurofilament light (NfL) protein is a marker of neuro-axonal damage and can be measured
not only in cerebrospinal fluid but also in serum, which allows for repeated assessments …
not only in cerebrospinal fluid but also in serum, which allows for repeated assessments …
Neurofilaments as biomarkers in neurological disorders
Neuroaxonal damage is the pathological substrate of permanent disability in various
neurological disorders. Reliable quantification and longitudinal follow-up of such damage …
neurological disorders. Reliable quantification and longitudinal follow-up of such damage …